Cabiralizumab

Drug Profile

Cabiralizumab

Alternative Names: BMS-986227; FPA-008; ONO-4687

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Five Prime Therapeutics
  • Developer Bristol-Myers Squibb; Five Prime Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Colony stimulating factor receptor antagonists; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pigmented villonodular synovitis
  • Phase I Cancer; Solid tumours
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 08 Aug 2017 Five Prime Therapeutics plans a pivotal trial for cabiralizumab in Pigmented villonodular synovitis
  • 04 Jun 2017 Interim safety and efficacy data from a phase I/II trial in Pigmented villonodular synovitis released by Five Prime Therapeutics
  • 25 May 2017 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in Japan (IV) (NCT03158272)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top